

China Human Vaccine Industry Report, 2015-2018

Mar. 2015

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- ◆ To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- ◆ To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- ◆ To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- ◆ To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- ◆ To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Abstract

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies' (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China's human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.

Affected by China's less-developed economy, existing national vaccine prevention policies and people's awareness of epidemic prevention, free EPI vaccines prevail in China with a share of about 80% in the total lot release volume. Chinese free human vaccine market is still dominated by Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises, but their market shares are falling. In 2014, the EPI vaccine lot release volume of Chinese state-owned enterprises accounted for 72%, down 6.5 percentage points compared with the previous year.


However, as China gradually relaxes control over the vaccine market, private companies and foreign players are emerging in market segments of extra EPI vaccine, with their proportions increasing constantly, accounting for 80% in terms of lot release volume. Moreover, private and foreign brands hold a dominant position in the markets of Haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, and influenza vaccine, together making up 91.9%, 83.6%, 86.5%, and 69.5% in terms of lot release volume in 2014.

Being bullish about China's demand for human vaccines and exports, many vaccine producers scale up efforts in vaccine R&D or expand capacity, such as Walvax Biotechnology. By early 2015, GMP on-site certification had been carried out for the company's Diphtheria-tetanus-acellular pertussis combined vaccine adsorbed; HPV bivalent (types 16 and 18) vaccine and DTaP/Hib had made their way into clinical trials; the company is applying registration for meningococcal polysaccharide vaccine (Group A/C/Y/W 135) and other vaccines in Nigeria, Chile, Peru, Thailand, and India.

China Human Vaccine Industry Report, 2015-2018 highlights the following:

- Operating environment, overall situation, sales channel, etc. of China human vaccine industry;
- Supply & demand, competitive landscape, import & export, and development forecast of the Chinese human vaccine market;
- Supply & demand, competitive landscape, and market prices of 10 product segments (including hepatitis B vaccine, influenza vaccine, rabies vaccine, and pneumococcal vaccine) in China;
- Operation, vaccine business, and development prospects of 16 Chinese human vaccine companies.

Competition Structure (by Lot Release Quantity) of Some Extra EPI Vaccines in China, 2014



Source : China Human Vaccine Industry Report , 2015-2018

Copyright 2012ResearchInChina

1 Overview of Vaccine Industry

- 1.1 Definition and Classification
- 1.2 Industry Chain

2 Overview of China Human Vaccine Industry & Market

- 2.1 Overview
- 2.2 Operating Environment
 - 2.2.1 International Market
 - 2.2.2 Policy Environment
- 2.3 Status Quo
- 2.4 Supply & Demand
- 2.5 Competitive Landscape
- 2.6 Developments
- 2.7 Sales Channel

3. Human Vaccine Market Segments in China

- 3.1 Hepatitis B Vaccine
 - 3.1.1 Supply & Demand
 - 3.1.2 Competitive Landscape
 - 3.1.3 Market Price
- 3.2 Meningococcal Vaccine
 - 3.2.1 Supply & Demand
 - 3.2.2 Competitive Landscape
 - 3.2.3 Market Price
 - 3.2.4 Market Forecast
- 3.3 Hepatitis A Vaccine

- 3.3.1 Supply & Demand
- 3.3.2 Competitive Landscape
- 3.3.3 Market Price
- 3.3.4 Market Forecast
- 3.4 Influenza Vaccine
 - 3.4.1 Supply & Demand
 - 3.4.2 Competitive Landscape
 - 3.4.3 Market Price
- 3.5 Hib Vaccine
 - 3.5.1 Supply & Demand
 - 3.5.2 Competitive Landscape
 - 3.5.3 Market Price
 - 3.5.4 Market Forecast
- 3.6 Human Rabies Vaccine
 - 3.6.1 Supply & Demand
 - 3.6.2 Competitive Landscape
 - 3.6.3 Market Price
 - 3.6.4 Market Forecast
- 3.7 Varicella Vaccine
 - 3.7.1 Supply & Demand
 - 3.7.2 Competitive Landscape
 - 3.7.3 Market Price
- 3.8 Pneumococca Vaccine
 - 3.8.1 Supply & Demand
 - 3.8.2 Competitive Landscape
 - 3.8.3 Market Price
- 3.9 DTP Vaccine

- 3.9.1 Supply & Demand
- 3.9.2 Competitive Landscape
- 3.9.3 Market Development & Forecast
- 3.10 Poliomyelitis Vaccine
 - 3.10.1 Supply & Demand
 - 3.10.2 Competitive Landscape

4 China's Import and Export of Vaccines

- 4.1 Export
 - 4.1.1 Export Volume and Value
 - 4.1.2 Export Destinations
- 4.2 Import
 - 4.2.1 Import Volume and Value
 - 4.2.2 Sources of Imported Vaccines

5 Major Chinese Vaccine Producers

- 5.1 China National Biotec Group Co., Ltd.
 - 5.1.1 Beijing Tiantan Biological Products Co., Ltd.
 - 5.1.2 Chengdu Institute of Biological Products Co., Ltd.
 - 5.1.3 Shanghai Institute of Biological Products Co., Ltd.
 - 5.1.4 Wuhan Institute of Biological Products Co., Ltd.
 - 5.1.5 Lanzhou Institute of Biological Products Co., Ltd.
 - 5.1.6 Changchun Institute of Biological Products Co., Ltd.
- 5.2 Hualan Biological Engineering Inc.
 - 5.2.1 Profile
 - 5.2.2 Operation
 - 5.2.3 Revenue Structure

5.2.4 Gross Margin	5.6 Liaoning Chengda Co., Ltd.	5.11.2 Operation
5.2.5 Customers and Suppliers	5.6.1 Profile	5.12 NCPC GeneTech Biotechnology Development Co., Ltd.
5.2.6 R&D and Investment	5.6.2 Operation	5.12.1 Profile
5.2.7 Vaccine Business	5.6.3 Revenue Structure	5.12.2 Operation
5.2.8 Development Prospect and Forecast	5.6.4 Gross Margin	5.13 Dalian Aleph Biomedical Co., Ltd.
5.3 Chongqing Zhifei Biological Products Co., Ltd.	5.6.5 Major Customers	5.13.1 Profile
5.3.1 Profile	5.6.6 Liaoning Chengda Biotechnology Co., Ltd	5.13.2 Operation
5.3.2 Operation	5.6.7 Development Prospect and Forecast	5.14 Beijing Minhai Biotechnology Co., Ltd.
5.3.3 Revenue Structure	5.7 Changchun BCHT Biotechnology Co. Ltd.	5.14.1 Profile
5.3.4 Gross Margin	5.7.1 Profile	5.14.2 Operation
5.3.5 Major Customers	5.7.2 Operation	5.15 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
5.3.6 R&D and Investment	5.8 Changchun Changsheng Life Sciences Limited	5.15.1 Profile
5.3.7 Development Prospect and Forecast	5.8.1 Profile	5.15.2 Operation
5.4 Walvax Biotechnology Co., Ltd.	5.8.2 Operation	5.16 Jiangsu Simcere Vaxtec Bio-pharmaceutical Co., Ltd.
5.4.1 Profile	5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.	
5.4.2 Operation	5.9.1 Profile	
5.4.3 Revenue Structure	5.9.2 Operation	
5.4.4 Gross Margin	5.10 Shenzhen Kangtai Biological Products Co. Ltd.	
5.4.5 Customers and Suppliers	5.10.1 Profile	
5.4.6 R&D and Investment	5.10.2 Operation	
5.4.7 Development Prospect and Forecast	5.11 Dalian Hissen Bio-pharm Co., Ltd.	
5.5 Sinovac Biotech Ltd.	5.11.1 Profile	
5.5.1 Profile		
5.5.2 Operation		
5.5.3 Revenue Structure		
5.5.4 R&D and Investment		

- Classification of Vaccines
- Vaccine Industry Chain
- Global Human Vaccine Market Size, 2008-2014
- Revenue of Global Top5 Human Vaccine Producers, 2008-2014
- Main Mergers & Acquisitions in Vaccine Industry Worldwide, 2005-2014
- Policies on Vaccine Industry in China
- Revenue and Total Profit of Bio-pharmaceutical Industry in China, 2007-2014
- Chinese Human Vaccine Market Size, 2007-2014
- Main Human Vaccine Varieties and Producers in China
- Gross Margin of Vaccine Business of Major Vaccine Companies in China, 2007-2014
- Lot Release Volume of EPI Vaccines and Extra EPI Vaccines, 2007-2014
- China's EPI Human Vaccine Market Shares by Lot Release Volume, 2008-2014
- China's Extra EPI Human Vaccine Market Shares by Lot Release Volume, 2008-2014
- Vaccine Business Revenue of Major Vaccine Companies in China, 2011-2014
- Human Vaccines under Review of CFDA, 2014
- Events Related to Vaccine Business of Foreign Companies in China, 2011-2014
- Diagram of Vaccine Distribution Channel in China
- Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2007-2014
- Hepatitis B Vaccine (CHO Cell) Suppliers and Lot Release Volume in China, 2008-2014
- Hepatitis B Vaccine (Yeast) Suppliers and Lot Release Volume in China, 2007-2014
- Market Price of Hepatitis B Vaccine in Some Parts of China, 2014
- Epidemic Meningitis Morbidity and Mortality in China, 2008-2013
- Meningococcal Vaccine Lot Release Volume in China by Type, 2007-2014
- Suppliers and Lot Release Volume of A-Group Meningococcal Vaccine, 2007-2014 (Million Doses)
- Suppliers and Lot Release Volume of A-Group Meningococcal Vaccine, 2009-2014 (Million Bottles)

- Suppliers and Lot Release Volume of A+C Meningococcal Vaccine, 2007-2014
- Suppliers and Lot Release Volume of ACYW135 Meningococcal Vaccine in China, 2008-2014
- Market Prices of Meningococcal Vaccine in Some Parts of China, 2014
- Hepatitis A Morbidity and Mortality in China, 2008-2013
- Hepatitis A Vaccine Lot Release Volume in China, 2007-2014
- Suppliers and Lot Release Volume of Hepatitis A Vaccine in China, 2007-2014
- Market Prices of Hepatitis A Vaccine in Some Parts of China, 2014
- China's Demand for Hepatitis A Vaccine, 2014-2018E
- Influenza Morbidity and Mortality in China, 2008-2013
- H1N1 Influenza Morbidity and Mortality in China, 2009-2012
- Influenza Vaccine Lot Release Volume in China by Type, 2007-2014
- Suppliers and Lot Release Volume of Influenza Split Vaccine in China, 2007-2014
- Suppliers and Lot Release Volume of Subunit Influenza Vaccine in China, 2007-2012
- Market Prices of Influenza Vaccine in Some Parts of China, 2014
- Hib Vaccine Lot Release Volume in China, 2007-2014
- Suppliers and Lot Release Volume of Hib Vaccine in China, 2007-2014
- Market Prices of Hib Vaccine in Some Parts of China, 2014
- Sales Volume of Hib Vaccine in China, 2014-2018E
- Rabies Morbidity and Mortality in China, 2007-2013
- Human Rabies Vaccine Lot Release Volume in China, 2007-2014
- Human Rabies Vaccine Lot Release Volume in China by Type, 2007-2014
- Suppliers and Lot Release Volume of Human (Vero Cell) Rabies Vaccine in China, 2007-2014
- Suppliers and Lot Release Volume of Human (BHK Cell) Rabies Vaccine in China, 2007-2014
- Market Prices of Human Rabies Vaccine in Some Provinces of China, 2014
- China's Demand for Human Rabies Vaccine in China, 2013-2018E

- Varicella Vaccine Lot Release Volume in China, 2007-2014
- Suppliers and Lot Release Volume of Varicella Vaccine in China, 2007-2014
- Market Price of Varicella Vaccine in Some Parts of China, 2014
- Pneumococcal Vaccine Lot Release Volume in China, 2007-2014
- Suppliers and Lot Release Volume of 7-valent and 23-valent Pneumococcal Vaccines in China, 2007-2014
- Market Prices of Pneumococcal Vaccine in Some Parts of China, 2014
- DPT Vaccine Lot Release Volume in China, 2007-2014
- Acellular PDT Vaccine Lot Release Volume in China, 2007-2014
- Poliomyelitis Vaccine Lot Release Volume in China, 2007-2014
- Poliomyelitis Vaccine Suppliers and Lot Release Volume in China, 2007-2014
- Export Volume and Value of Human Vaccines in China, 2009-2014
- Average Export Prices of Human Vaccines in China, 2009-2014
- Destinations of Exported Human Vaccines from China, 2014
- Import Volume and Value of Human Vaccines in China, 2009-2014
- Average Import Prices of Human Vaccines in China, 2009-2014
- Sources of Imported Human Vaccines in China, 2014
- Subsidiaries and Their Revenue and Profit of Beijing Tiantan Biological Products, 2014
- Revenue and Operating Income of Beijing Tiantan Biological Products, 2007-2014
- Revenue Breakdown of Beijing Tiantan Biological Products by Sector, 2007-2014
- Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2007-2014
- Beijing Tiantan Biological Products' Procurement from Top5 Suppliers and % of Total Procurement, 2007-2014
- Beijing Tiantan Biological Products' Revenue from Top5 Customers and % of Total Revenue, 2007-2014
- Gross Margin of Beijing Tiantan Biological Products by Sector, 2007-2014
- R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2009-2014
- Vaccine Revenue of Beijing Tiantan Biological Products, 2007-2014

- Vaccine Lot Release Volume Breakdown of Beijing Tiantan Biological Products by Product, 2009-2014
- Revenue and Operating Income of Beijing Tiantan Biological Products, 2014-2018E
- Vaccine Varieties of Chengdu Institute of Biological Products
- Vaccine Lot Release Volume Breakdown of Chengdu Institute of Biological Products by Product, 2009-2014
- Vaccine Varieties of Shanghai Institute of Biological Products
- Vaccine Lot Release Volume Breakdown of Shanghai Institute of Biological Products by Product, 2009-2014
- Vaccine Lot Release Volume Breakdown of Wuhan Institute of Biological Products by Product, 2009-2014
- Vaccine Lot Release Volume Breakdown of Lanzhou Institute of Biological Products by Product, 2009-2014
- Vaccine Lot Release Volume Breakdown of Changchun Institute of Biological Products by Product, 2009-2014
- Revenue and Operating Income of Hualan Biological Engineering, 2007-2014
- Revenue Breakdown of Hualan Biological Engineering by Sector, 2007-2014
- Gross Margin of Hualan Biological Engineering by Product, 2007-2014
- Hualan Biological Engineering's Revenue from Top5 Customers and % of Total Revenue, 2007-2014
- Hualan Biological Engineering's Procurement from Top5 Suppliers and % of Total Procurement, 2007-2014
- R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2007-2014
- Lot Release Volume Breakdown of Hualan Biological Engineering by Product, 2011-2014
- Vaccine Revenue and Gross Margin of Hualan Biological Engineering, 2008-2014
- Revenue and Operating Income of Hualan Biological Engineering, 2014-2018E
- Subsidiaries and Main Products of Chongqing Zhifei Biological Products
- Revenue and Operating Income of Chongqing Zhifei Biological Products, 2008-2014
- Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2014
- Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2014
- Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2009-2014
- Gross Margin of Chongqing Zhifei Biological Products, 2009-2014
- Gross Margins of Chongqing Zhifei Biological Products' Home-grown Vaccines, 2008-2014

- Gross Margins of Chongqing Zhifei Biological Products' Agent Vaccines, 2008-2014
- Chongqing Zhifei Biological Products' Revenue from Top5 Customers and % of Total Revenue, 2008-2014
- R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2008-2014
- Progress of the Products under Research of Chongqing Zhifei Biological Products by the end of 2014
- Revenue and Operating Income of Chongqing Zhifei Biological Products, 2014-2018E
- Industrial Layout of Walvax Biotechnology
- Revenue and Operating Income of Walvax Biotechnology, 2009-2014
- Vaccines on the Market and Capacities of Walvax Biotechnology
- Revenue Breakdown of Walvax Biotechnology by Product, 2009-2014
- Lot Release Volume Breakdown of Walvax Biotechnology by Product, 2009-2014
- Revenue Breakdown of Walvax Biotechnology by Region, 2010-2014
- Gross Margin of Walvax Biotechnology by Product, 2007-2014
- Walvax Biotechnology's Revenue from Top5 Customers and % of Total Revenue, 2008-2014
- Walvax Biotechnology's Procurement from Top5 Suppliers and % of Total Procurement, 2008-2014
- Progress of Projects under Construction of Walvax Biotechnology by the end of 2014
- R&D Costs and % of Total Revenue of Walvax Biotechnology, 2009-2014
- Progress of the Products under Research of Walvax Biotechnology by the end of 2014
- Revenue and Operating Income of Walvax Biotechnology, 2014-2018E
- Revenue and Operating Income of Sinovac Biotech, 2008-2014
- Revenue Breakdown of Sinovac Biotech by Product, 2008-2014
- Vaccine Lot Release Volume Breakdown of Sinovac Biotech by Product, 2009-2014
- R&D Costs and % of Total Revenue of Sinovac Biotech, 2008-2013
- Revenue and Operating Income of Liaoning Chengda, 2008-2014
- Revenue Breakdown of Liaoning Chengda by Sector, 2008-2013
- Revenue Breakdown of Liaoning Chengda by Region, 2008-2014

- Gross Margin of Liaoning Chengda by Sector, 2008-2014
- Liaoning Chengda's Revenue from Top5 Customers and % of Total Revenue, 2008-2014
- Name List and Revenue Contribution of Liaoning Chengda's Top 5 Customers, 2013
- Human Vaccine Lot Release Volume of Liaoning Chengda Biotechnology, 2009-2014
- Revenue and Net Income of Liaoning Chengda Biotechnology, 2012-2014
- Revenue Structure of Liaoning Chengda Biotechnology by Product, 2012-2014
- Name List and Revenue Contribution of Liaoning Chengda Biotechnology's Top5 Customers, 2013-2014
- Name List and Procurement Share of Liaoning Chengda Biotechnology's Top5 Suppliers, 2013-2014
- Revenue and Operating Income of Liaoning Chengda, 2014-2018E
- Revenue and Operating Income of Changchun BCHT Biotechnology, 2009-2014
- Vaccine Lot Release Volume Breakdown of Changchun BCHT Biotechnology by Product, 2009-2014
- Lot Release Volume Breakdown of Changchun Changsheng Life Sciences by Product, 2008-2014
- Vaccines of Zhejiang Tianyuan Bio-Pharmaceutical
- Vaccine Lot Release Volume Breakdown of Zhejiang Tianyuan Bio-Pharmaceutical by Product, 2009-2014
- Revenue and Operating Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
- Assets and Liabilities of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
- Hepatitis B Vaccine Lot Release Volume Breakdown of Shenzhen Kangtai Biological Products by Dosage Form, 2007-2014
- Vaccine Lot Release Volume Breakdown of Dalian Hissen Bio-pharm by Product, 2009-2014
- Vaccines under Research of Dalian Hissen Bio-pharm, 2014
- Vaccine Lot Release Volume of NCPC GeneTech Biotechnology Development, 2009-2014
- Lot Release Volume of Dalian Aleph Biomedical, 2009-2014
- Revenue and Operating Income of Dalian Aleph Biomedical, 2013-2014
- Assets and Liabilities of Dalian Aleph Biomedical, 2013-2014
- Vaccines under Research of Beijing Minhai Biotechnology
- Vaccine Lot Release Volume Breakdown of Beijing Minhai Biotechnology by Product, 2009-2014

- 
- Revenue and Operating Income of Beijing Minhai Biotechnology, 2013-2014
 - Assets and Liabilities of Beijing Minhai Biotechnology, 2013-2014
 - Vaccine Lot Release Volume Breakdown of Shenzhen Sanofi Pasteur Biological Products by Product, 2009-2014
 - Revenue and Operating Income of Shenzhen Sanofi Pasteur Biological Products, 2013-2014
 - Assets and Liabilities of Shenzhen Sanofi Pasteur Biological Products, 2013-2014

You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828/ 82601561

Party A:			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

Party B:			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 502, Block 3, Tower C, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	report@researchinchina.com	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng, Landianchang, Haidian District, Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG		

Title	Format	Cost
<i>Total</i>		

Choose type of format

- PDF (Single user license)2,500 USD
- Hard copy 2,650 USD
- PDF (Enterprisewide license)..... 3,900 USD

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via PayPal.

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- *Multi-users market reports*
- *Database-RICDB*
- *Custom Research*
- *Company Search*

RICDB (<http://www.researchinchina.com/data/database.html>), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at: